Gilead Sciences, Inc. (GILD) Shares Sold by Norinchukin Bank The

Norinchukin Bank The cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 164,025 shares of the biopharmaceutical company’s stock after selling 18,802 shares during the quarter. Norinchukin Bank The’s holdings in Gilead Sciences were worth $13,289,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. raised its stake in shares of Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Gilead Sciences by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after purchasing an additional 310,607 shares during the last quarter. FMR LLC raised its stake in shares of Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after purchasing an additional 116,780 shares during the last quarter. Institutional investors own 76.06% of the company’s stock.

In other news, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Insiders sold 591,666 shares of company stock worth $44,466,567 over the last ninety days. Corporate insiders own 1.30% of the company’s stock.

GILD has been the topic of several analyst reports. Mizuho reaffirmed a “buy” rating on shares of Gilead Sciences in a report on Friday, September 29th. Jefferies Group reaffirmed a “hold” rating and set a $93.00 target price on shares of Gilead Sciences in a report on Wednesday, October 4th. Bank of America dropped their target price on Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating on the stock in a report on Wednesday, October 4th. Oppenheimer initiated coverage on Gilead Sciences in a report on Thursday, October 5th. They set a “market perform” rating on the stock. Finally, CIBC initiated coverage on Gilead Sciences in a report on Thursday, October 5th. They set a “market perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eighteen have assigned a buy rating to the stock. Gilead Sciences has an average rating of “Buy” and a consensus price target of $85.53.

Shares of Gilead Sciences, Inc. (GILD) opened at $80.98 on Monday. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27. The company has a market capitalization of $105,781.67, a P/E ratio of 9.22, a price-to-earnings-growth ratio of -1.76 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same period last year, the company earned $2.75 earnings per share. Gilead Sciences’s quarterly revenue was down 13.2% compared to the same quarter last year. equities research analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date was Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.69%.

TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Shares Sold by Norinchukin Bank The” was first published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.truebluetribune.com/2018/01/22/gilead-sciences-inc-gild-shares-sold-by-norinchukin-bank-the.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply